Hong Kong Med J 2003;9:243-6 | Number 4, August 2003
Dexfenfluramine and heart-valve regurgitation in Chinese patients with type 2 diabetes
GTC Ko, HCK Chan, CC Chow
Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong
OBJECTIVE. To assess whether valvular lesions are associated with the use of dexfenfluramine in Chinese patients with type 2 diabetes.
DESIGN. Case-control study.
PATIENTS AND METHODS. Thirty-six obese Chinese patients with type 2 diabetes and a history of dexfenfluramine use during the period January 1992 and September 1997 were recruited into the study, while another 43 age- and sex-matched Chinese patients with type 2 diabetes were recruited as controls. The mean age for the cases was 44.1 years (standard deviation, 11.2 years; median, 42.5 years; range, 20-64 years). The 43 control subjects were age- and sex-matched, and had a mean age of 48.5 years (standard deviation, 10.9 years; median, 51.0 years; range, 16-63 years; P>0.05). The male-to-female ratio was confirmed as similar between the two groups (10:26 versus 12:31; P>0.05). All patients were clinically free from cardiovascular disease. Patients with a history of underlying valvular disease from any cause were excluded from the study. All patients underwent echocardiographic assessment, and the presence of any valvular lesions was documented.
RESULTS. The mean duration of dexfenfluramine use by the cases was 21.8 weeks (standard deviation, 29.0 weeks; median, 18.0 weeks; range, 1-160 weeks). Subjects with a history of dexfenfluramine use had higher rates of ignificant aortic regurgitation, tricuspid regurgitation of any severity, and of any valvular regurgitation, compared to controls (11.1% versus 0%, P
CONCLUSION. In Chinese patients with type 2 diabetes, a history of dexfenfluramine use is associated with heart-valve regurgitation, particularly aortic regurgitation.
Key words: Chinese; Dexfenfluramine; Diabetes mellitus; Heart valves
View this abstract indexed in MEDLINE: